SCIENTIFIC LETTERS

Sarcoidosis developing after treatment with interferon alpha in a patient with hepatitis C: An association every physician should know

Sarcoidosis posterior a tratamiento con interferón alfa en paciente con hepatitis C: una asociación que todo médico debería conocer

Sarcoidosis is a chronic granulomatous disease of unknown etiology that basically affects lung and adenopathic tissue, although it can involve any tissue. Its diagnosis requires the combination of clinical, radiologic, and histologic findings and treatment varies according to its severity. Interferon has been implicated in the etiology of the formation of granulomas and in 1987 the first case of sarcoidosis secondary to the use of interferon alpha was reported. Approximately 100 cases of sarcoidosis related to the use of interferon have been published in the literature. Interferon is currently a widely used therapy for the treatment of hepatitis C. We present herein the case of a 48-year-old woman that presented with pain in both knees of one-month progression. Her past history included hepatopathy from the hepatitis C virus treated with triple therapy (telaprevir + interferon + ribavirin), which ended 2 months prior to symptom onset. Physical examination revealed 2 hardened, erythematous zones above the right knee with increased local temperature and no lesions in the pretilial zone (fig. 1). The analytic parametric studies were normal (ANAs, RF, ESR, and CRP, slightly elevated ACE) and the Mantoux test was negative. Chest x-ray revealed modest perihilar thickening. It was confirmed by tomography scan that also identified adenopathic perihilar and mediastinic conglomerates. Respiratory function tests were normal. Biopsy of the nodular lesions reported changes consistent with «subcutaneous sarcoidosis» (fig. 2). Follow-up and surveillance were decided upon. The patient had clinical improvement and symptoms disappeared 6 months later. All diagnoses of sarcoidosis within the last 2 years were reviewed in our hospital database and we found no other similar case.

There is a clear relation between the appearance of sarcoidosis and interferon alpha use and various cases of sarcoidosis activation/reactivation during the disease course of patients with hepatitis C virus undergoing said treatment. Symptoms can occur during treatment or up to 2 years after its suspension. Nevertheless, it is difficult to know the incidence of this entity.

Even though the natural history of sarcoidosis is highly variable, in one study of patients with interferon-associated

---

Please cite this article as: Flores-Robles BJ, Sangüesa-Gómez CP, Barbadillo Mateos C, Roustán-Gullón LG, Kovtun I. Sarcoidosis posterior a tratamiento con interferón alfa en paciente con hepatitis C: una asociación que todo médico debería conocer. Revista de Gastroenterología de México. 2017;82:185–186.
sarcoïdosis, 85% of the patients were spontaneously cured and 10% of the cases became chronic, utilizing corticoids in the most severe cases.² Other treatments that have been used are hydroxychloroquine³⁶ and infliximab.¹¹ The administration of corticoids can increase the viral burden and hepatitis C virus itself induces interferon alpha expression. ¹²

It is relatively common in medical consultations to find patients with hepatitis C virus, therefore if there are symptoms that lead to suspicion of sarcoïdosis, the physician must take into account the association of this entity with interferon alpha use.

Funding

No financial support was received in relation to this study/article.

Conflict of interest

The authors declare that there is no conflict of interest.

References


B.J. Flores-Robles¹, C.P. Sangüesa-Gómez², C. Barbadillo Mateos³, L.G. Roustán-Gullón⁴, I. Koutun⁵

¹ Rheumatology Service, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain
² Dermatology Service, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain
³ Pathologic Anatomy Service, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain

*Corresponding author. Servicio de Reumatología, Hospital Universitario Puerta de Hierro-Majadahonda, Manuel de Falla no 1, Majadahonda, Madrid, Spain. Tel.: +3495521497. E-mail address: aldolasa@hotmail.com (B.J. Flores-Robles).

2255-534X/© 2016 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

---

Severe complications of acute appendicitis with the laparoscopic approach

Complicaciones graves de appendicitis aguda con abordaje laparoscópico

Acute appendicitis is one of the surgically resolved abdominal pathologies with the highest incidence, occurring in 7% of the general population.¹ Fortunately it has a low mortality rate under 0.1%.²–⁴

A 44-year-old man, who came to us from another hospital, had a relevant personal history of long progression type 2 diabetes mellitus that was apparently well controlled, and he had undergone a laparoscopic appendectomy on April 12, 2015 (38 days before we saw him). Phase III acute appendicitis was reported. It was defined as a venous infarction, total wall necrosis, and perforation, with the later formation of a localized abscess. Unfortunately, we had no detailed clinical report on the intraoperative findings or the surgical technique performed (use of antibiotic-impregnated sutures and/or preoperative asepsis and antisepsis measures). However, upon the patient’s admission to our hospital, we observed a 3-port approach. One was a transumbilical port, another was at the level of the left flank, and the other was suprapubic. The first 2 had cicatrizated, but abundant